RT Journal Article
SR Electronic
T1 Battle of Polio eradication in the Western Pacific Region in the transition to COVID-19 endemicity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.30.22282954
DO 10.1101/2022.11.30.22282954
A1 Mei, Ruobing
A1 Kwok, Shirley L. L.
A1 Lau, Eric H. Y.
A1 Lo, Tiffany H. K.
A1 Wu, Joseph T.
A1 Lin, Leesa K.
A1 Leung, Kathy
YR 2022
UL http://medrxiv.org/content/early/2022/12/03/2022.11.30.22282954.abstract
AB The Polio eradication campaign has been set back substantially since 2020 due to the COVID-19 pandemic. Recent detections of poliovirus transmission in multiple high-income countries suggest suboptimal population immunity in many parts of the world even though polio vaccination has been included in routine childhood immunization for decades. We reviewed polio vaccination schedules and vaccine uptake in the Western Pacific Region countries and assessed the potential shortfall in population immunity against polio resurgence across these populations. In addition, we conducted a repeated cross-sectional study between 2021 and 2022 in the Western Pacific Region to understand factors contributing to polio vaccine hesitancy. Our results reveal potential shortfalls in population immunity against polio in Western Pacific Region and provide insights into how vaccination programs and campaigns can be strengthened to ensure continual progress towards polio eradication.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the Vaccine Confidence Fund (#VCF-020), AIR@InnoHK administered by Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region, and Health and Medical Research Fund administered by the Health Bureau, The Government of the Hong Kong Special Administrative Region (HMRF COVID19F05). The funders have no other involvement in this study beyond financial support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board at the London School of Hygiene and Tropical Medicine (LSHTM 26636).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe collated data from publicly available secondary data sources. The sources of all secondary data included in the analyses are available in the main text or supplementary materials. Anonymised survey data will be made available to others upon request to the corresponding author with proposed data needs.